The University Hospital in Zürich has just published a clinical article describing the use of Vivostat Fibrin Sealant in lung surgery1. Using Vivostat Fibrin Sealant, the research team obtained more than 80% reduction in prolonged air leaks and a 50% reduction in drainage time for patients undergoing lung volume reduction surgery.
The study was performed independently of Vivostat A/S by the Division of Thoracic Surgery at the University Hospital in Zürich, Switzerland and lead by Professor Lardinois.
The surgical procedure called ”lung volume reduction surgery” is a procedure used for patients suffering from lung emphysema, i.e. lungs that do not operate properly due to swelling of the lungs. During this procedure a part of the lung is surgically removed and a very common post-surgical complication is leaking of air from the remaining lung tissue.
Vivostat® Fibrin Sealant is a patient-derived product that extracts the coagulation factors (the “fibrin”) from the individual patient’s blood. After removal of the lung tissue, the fibrin sealant is applied to the lung surface to seal the remaining area and thereby avoid air leaks from the lung.
“This is our third clinical publication describing the benefits of using Vivostat Fibrin Sealant in lung surgery”, says Tom Bjerg Lauritzen, CEO of Vivostat A/S. “Not only does it again show very good results that will help the patient to a faster and less painful recovery; the surgeons also conclude that our product isfar more efficient than other products on the market and easier to use.
Tom Bjerg Lauritzen continues, ”Until recently we have focused our effort in the cardiac area, but with the increasing number of positive results in lung surgery, we will also dedicate substantial resources to approach the thoracic segment. We have recently established direct sales forces in Germany and the UK to ensure full control of the sales channels and this will be an important tool in our effort to target the thoracic segment effectively”.
Within the worldwide surgical sealant market of USD 800 million, it is estimated that almost half of the products are used in cardiothoracic and vascular procedures. Following an increasing concern related to the risk of using surgical sealants based on human donor blood and animal derived components, the market is moving towards safer products, such as Vivostat patient-derived fibrin sealant.
References:
1. Autologous fibrin sealant reduces the incidence of prolonged air leak and duration of chest tube drainage after lung volume reduction surgery: A prospective randomized blinded study
The Journal of Thoracic and Cardiovascular Surgery , Volume 136 , Issue 4 , Pages 843 - 849 C . Moser , I . Opitz , W . Zhai , V . Rousson , E . Russi , W . Weder , D . Lardinois
About VIVOSTAT
Vivostat A/S is a privately owned company based in the Medicon Valley of Scandinavia. Our products, Vivostat® Fibrin Sealant and Vivostat® PRF® (Platelet Rich Fibrin), utilizes the patient’s own blood to derive either a surgical sealant to prevent and stop bleedings, or a gel with a high concentration of growth factors (PRF®) that stimulates the healing of chronic wounds. By using the patient’s own blood there is no risk of allergic reactions or transfer of viral diseases. This is an increasingly important factor as more and new viruses, such as Avian bird flu etc., develop. Our products are sold through direct sales organisations and distributors throughout Europe and Asia - mainly to surgical departments and wound care centres. More than 98% of our sale is export.
